Effect of ethanolic extract of
Anti-inflammatory
IL-1beta
Stachys pilifera Benth
TNF-alpha
TPA
Journal
Research in pharmaceutical sciences
ISSN: 1735-5362
Titre abrégé: Res Pharm Sci
Pays: Iran
ID NLM: 101516968
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
22
10
2020
revised:
31
01
2021
accepted:
01
08
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
This study was designed to evaluate the anti-inflammatory activities of S. pilifera (HESP) in two sub-acute models of inflammation and clarified some possible mechanisms. Colorimetric methods were used to determine total phenol and flavonoid contents. Carrageenan or formalin-induced rat paw edema (seven days) and multiple application TPA-induced ear edema in mice (9 days) were used. The concentration of IL-1 and TNF-α were measured in the inflamed paw, as well as MDA levels in the serum and liver. Histopathological studies and Total phenol and flavonoid contents of HESP were 101.35 ± 2.96 mg GAE/g extract and 660.79 ± 10.06 mg RE g extract, respectively. Oral (100 and 200 mg/kg) and topical application (5 mg/ear) of HESP significantly inhibited formalin-induced paw edema and multiple TPA-induced ear edema. The extract also significantly decreased the serum and liver levels of MDA in the carrageenan and formalin tests. The elevated levels of TNF-α and IL-1β in the carrageenan-injected paw were not affected by HESP. The extract (50-800 μg/mL) inhibited heat-or hypotonicity-induced hemolysis. Histopathological examination of the inflamed tissues revealed that HESP inhibited congestion and leukocyte infiltration. The findings confirmed the potent anti-inflammatory effects of
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
This study was designed to evaluate the anti-inflammatory activities of S. pilifera (HESP) in two sub-acute models of inflammation and clarified some possible mechanisms.
EXPERIMENTAL APPROACH
METHODS
Colorimetric methods were used to determine total phenol and flavonoid contents. Carrageenan or formalin-induced rat paw edema (seven days) and multiple application TPA-induced ear edema in mice (9 days) were used. The concentration of IL-1 and TNF-α were measured in the inflamed paw, as well as MDA levels in the serum and liver. Histopathological studies and
FINDINGS/RESULTS
RESULTS
Total phenol and flavonoid contents of HESP were 101.35 ± 2.96 mg GAE/g extract and 660.79 ± 10.06 mg RE g extract, respectively. Oral (100 and 200 mg/kg) and topical application (5 mg/ear) of HESP significantly inhibited formalin-induced paw edema and multiple TPA-induced ear edema. The extract also significantly decreased the serum and liver levels of MDA in the carrageenan and formalin tests. The elevated levels of TNF-α and IL-1β in the carrageenan-injected paw were not affected by HESP. The extract (50-800 μg/mL) inhibited heat-or hypotonicity-induced hemolysis. Histopathological examination of the inflamed tissues revealed that HESP inhibited congestion and leukocyte infiltration.
CONCLUSION AND IMPLICATIONS
CONCLUSIONS
The findings confirmed the potent anti-inflammatory effects of
Identifiants
pubmed: 34522199
doi: 10.4103/1735-5362.323918
pii: RPS-16-516
pmc: PMC8407160
doi:
Types de publication
Journal Article
Langues
eng
Pagination
516-527Informations de copyright
Copyright: © 2021 Research in Pharmaceutical Sciences.
Déclaration de conflit d'intérêts
The authors declared no conflict of interest in this study.
Références
Res Pharm Sci. 2020 Dec 30;16(1):94-102
pubmed: 33953778
Phytomedicine. 1999 Oct;6(4):267-72
pubmed: 10589446
Nature. 2002 Dec 19-26;420(6917):846-52
pubmed: 12490957
J Ethnopharmacol. 2007 Aug 15;113(1):142-8
pubmed: 17616291
J Ethnopharmacol. 2017 Feb 23;198:407-416
pubmed: 28119101
Eur J Pharmacol. 2001 Sep 28;428(1):137-43
pubmed: 11779030
Indian J Pharmacol. 2015 May-Jun;47(3):292-8
pubmed: 26069367
Pharm Biol. 2017 Dec;55(1):1389-1393
pubmed: 28317417
Curr Drug Discov Technol. 2021;18(3):405-413
pubmed: 32072913
J Food Biochem. 2020 May;44(5):e13190
pubmed: 32155675
Iran Red Crescent Med J. 2014 Sep 05;16(9):e19259
pubmed: 25593730
Biomed Pharmacother. 2017 Feb;86:95-101
pubmed: 27974282
Int J Cancer. 2002 Aug 1;100(4):456-62
pubmed: 12115530
Res Pharm Sci. 2018 Oct;13(5):404-412
pubmed: 30271442
J Ethnopharmacol. 2018 Aug 10;222:239-248
pubmed: 29733944
Drug Dev Res. 2017 Nov;78(7):360-367
pubmed: 28776721
Jundishapur J Nat Pharm Prod. 2015 Feb 20;10(1):e22466
pubmed: 25866724
Res Pharm Sci. 2020 Feb 20;15(1):66-75
pubmed: 32180818
Scand J Gastroenterol. 2017 Sep;52(9):941-947
pubmed: 28587496
Exp Mol Pathol. 2013 Jun;94(3):419-29
pubmed: 23399806
J Ethnopharmacol. 2017 Apr 18;202:281-289
pubmed: 28242384
J Cell Biochem. 2019 Sep;120(9):14875-14884
pubmed: 31016763
Int Immunopharmacol. 2013 Mar;15(3):505-10
pubmed: 23415748
Mol Biol Rep. 2020 Jul;47(7):5001-5012
pubmed: 32533401
Pharmacol Res. 2002 Aug;46(2):133-9
pubmed: 12220952
Skin Pharmacol. 1991;4(4):262-71
pubmed: 1789987
Eur J Pharmacol. 2011 Sep 30;667(1-3):396-401
pubmed: 21645506
Cancer Res. 2000 Sep 15;60(18):5059-66
pubmed: 11016629
Heliyon. 2019 Dec 24;5(12):e03029
pubmed: 32382666
J Ethnopharmacol. 2018 Jun 12;219:103-109
pubmed: 29567276
J Tradit Complement Med. 2017 Apr 26;8(1):107-112
pubmed: 29321997